住友化学一季度利润反弹但维持全年展望

U.S.-Iran talks uncertain; Palantir, Snap report - what’s moving markets
Introduction & Market Context
Sumitomo Chemical presented its first quarter fiscal 2026 financial results on August 4, 2026, revealing a dramatic profit rebound that marked the company’s second-best first quarter performance on record. Despite the strong quarterly showing, the presentation maintained a cautious tone on the full-year outlook, citing geopolitical uncertainties and the temporary nature of some earnings drivers.
The Japanese chemical giant reported core operating income of ¥62.3 billion, more than doubling from ¥27.7 billion in the same quarter last year. Net income attributable to owners of the parent swung to ¥40.8 billion from a loss of ¥4.5 billion, representing a remarkable turnaround in profitability.
Quarterly Performance Highlights
As shown in the following summary of key financial metrics, Sumitomo Chemical delivered across multiple profit measures in the first quarter.
Sales revenue reached ¥578.2 billion in the first quarter, up 9.9% year-over-year from ¥526.1 billion. The company attributed the improvement to three primary factors: better profit margins at Petro Rabigh, a temporary gain from inventory valuation differences, strong crop protection product shipments, and improved feed additive margins.
The balance sheet also strengthened significantly. The debt-to-equity ratio improved to 0.80 times from 0.93 times as of March 2026, driven by strong business performance and Sumitomo Pharma’s capital increase of ¥97.8 billion.
The following detailed financial breakdown illustrates the comprehensive nature of the quarterly improvement.
Operating income surged 139.8% to ¥61.0 billion from ¥25.5 billion, while finance expenses improved dramatically, with gains on foreign currency transactions swinging to ¥1.6 billion from a loss of ¥16.4 billion in the prior year. Income before taxes reached ¥60.3 billion compared to just ¥5.8 billion a year earlier, a variance ratio of 936.8%.
Return on equity improved to 3.9% from negative 0.5% in the prior year quarter. The overseas sales revenue ratio remained high at 67.7%, though slightly down from 68.5% a year earlier.
Segment Performance Analysis
The company’s performance varied significantly across its reporting segments, with Essential & Green Materials and Agro & Life Solutions driving the profit growth while ICT & Mobility Solutions faced headwinds.
The following chart breaks down sales revenue changes by segment, showing the contribution from price, volume, and foreign exchange factors.
Essential & Green Materials posted sales revenue of ¥170.2 billion, up 2.9% from ¥165.4 billion, despite a significant decline in shipping volumes. Price improvements of ¥33.5 billion were partially offset by volume declines of ¥34.7 billion, with foreign currency conversion adding ¥6.0 billion.
Sumitomo Pharma showed the strongest revenue growth at 20.2%, reaching ¥129.0 billion compared to ¥107.4 billion in the prior year. This increase was driven primarily by shipping volume improvements of ¥12.6 billion and favorable foreign exchange effects of ¥9.5 billion.
Core operating income performance by segment revealed even more dramatic divergences, as illustrated in the following variance analysis.
Essential & Green Materials delivered the most striking turnaround, swinging to core operating income of ¥27.2 billion from a loss of ¥5.5 billion in the prior year quarter—an improvement of ¥32.7 billion. Price variance contributed ¥14.0 billion to this gain, while volume and other factors added ¥17.2 billion, including significant improvements from equity-method investments.
Agro & Life Solutions core operating income increased to ¥9.6 billion from ¥2.2 billion, driven primarily by price improvements of ¥6.5 billion in feed additives and steady crop protection shipments.
In contrast, ICT & Mobility Solutions saw core operating income decline to ¥13.0 billion from ¥18.4 billion, pressured by lower display-related product pricing and volumes, though partially offset by stronger semiconductor processing materials.
The detailed performance of the Essential & Green Materials segment, which provided the largest profit contribution, is shown in the following regional breakdown.
The segment benefited from improved profit margins in both Japan and Singapore, along with better refining margins at Petro Rabigh in Saudi Arabia. Management noted that while these improvements were substantial, some gains from inventory valuation differences are expected to reverse in the second quarter.
Balance Sheet Strength
The company’s financial position improved markedly during the quarter, as reflected in the following statement of financial position.
Total assets increased to ¥3,613.5 billion from ¥3,405.0 billion at fiscal year-end 2025, an increase of ¥208.5 billion. Current assets rose ¥151.3 billion, driven by increases in trade receivables (¥35.9 billion), inventories (¥48.1 billion), and other current assets (¥52.7 billion).
Interest-bearing liabilities decreased to ¥1,132.2 billion from ¥1,151.5 billion, a reduction of ¥19.3 billion despite the asset growth. Total equity increased ¥175.8 billion to ¥1,412.4 billion, with non-controlling interests rising ¥81.6 billion following Sumitomo Pharma’s capital increase.
The ratio of equity attributable to owners of the parent to total assets improved to 30.5% from 29.6%, reflecting the strengthened capital structure.
Forward-Looking Guidance
Management maintained its cautious stance on the full-year outlook while projecting strong first-half performance, as detailed in the following forecast summary.
For the first half of fiscal 2026, the company forecast core operating income of ¥125.0 billion, which would represent approximately ¥120.0 billion excluding gains on business sales—roughly double the prior year’s first-half performance when similarly adjusted. Net income attributable to owners of the parent is projected at ¥70.0 billion for the first half, matching the full-year forecast announced in May.
This implies that the company expects to achieve its annual net income target in just the first six months, suggesting a weaker second half ahead. Management attributed this projection pattern to the expected reversal of temporary inventory valuation gains and ongoing geopolitical uncertainties in the Middle East.
The detailed first-half forecast by segment reveals the expected profit distribution across business units.
Agro & Life Solutions is forecast to deliver core operating income of ¥29.0 billion in the first half, up from ¥11.2 billion in the prior year, driven by strong crop protection demand entering peak season and improved feed additive margins. Essential & Green Materials is projected at ¥42.0 billion compared to a loss of ¥18.6 billion in the prior year first half.
ICT & Mobility Solutions is expected to generate ¥28.0 billion in core operating income, down from ¥33.1 billion, as display-related headwinds persist despite semiconductor materials growth. Sumitomo Pharma’s first-half core operating income is forecast at ¥32.0 billion, down from ¥97.3 billion, which included significant gains from business sales in the prior year.
Outlook for Business Environment
The company outlined several key factors expected to influence performance in the first half, noting both supportive trends and persistent challenges.
On the macroeconomic front, management acknowledged that technology investments are supporting global economic activity but emphasized that geopolitical risks, particularly the deteriorating situation in the Middle East, create significant uncertainty for future business conditions.
For crop protection products, while current shipments remain solid, inventory congestion in distribution chains varies by region. Feed additive profit margins improved in the first quarter, but the outlook remains uncertain with raw material prices holding at elevated levels.
In the display business, the mobile device market is expected to remain sluggish due to increasingly challenging procurement conditions for memory chips and other components. However, demand for silicon semiconductors should remain solid, primarily driven by AI-related applications.
The petrochemicals and raw materials outlook indicates that while sufficient materials have been secured for current production plans, the impact of high raw material prices will continue to pressure margins in the near term.
Challenges and Risks
Despite the strong first-quarter results, the presentation highlighted several risk factors that could impact future performance. The temporary nature of some earnings drivers emerged as a key concern, with inventory valuation gains expected to reverse in the second quarter, creating a headwind for Essential & Green Materials.
Middle East geopolitical tensions continue to affect both supply chains and demand patterns, particularly impacting the Advanced Medical Solutions segment through profit margin pressure and creating uncertainty in feed additive raw material costs.
The ICT & Mobility Solutions segment faces structural challenges as the company winds down large-size display operations while ramping up semiconductor materials production. This transition involves significant fixed-cost increases from new investments that are limiting near-term profit growth even as semiconductor demand remains strong.
In the pharmaceutical business, Sumitomo Pharma is experiencing rising selling, general, and administrative expenses in North America along with increased R&D spending, which are expected to pressure profitability despite sales growth in key products like ORGOVYX and GEMTESA.
The company plans to provide a comprehensive full-year forecast update when announcing first-half financial results, suggesting that management is waiting for greater clarity on these risk factors before committing to revised annual guidance.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.